Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent or equivalent document (e.g., written information) as per country regulation prior to registration of any patient data~* Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option~* Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry~Exclusion Criteria:~* Patients with ectopic ACTH-dependent Cushing's syndrome~* Patients with adrenal Cushing's syndrome~* Patients with Pseudo Cushing's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1/new use cohort (Type: None): Subjects who initiated pasireotide s.c. at time of study entry (on or after the signing of the informed consent or acknowledging an equivalent document -for example, written information- as per country regulation).
- Cohort 2/prior use cohort (Type: None): Subjects who initiated pasireotide s.c. prior to study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).